Indeed, demand has surged so quickly that Novo Nordisk acknowledged it is experiencing "intermittent supply disruptions" for Ozempic. It attributed the shortage, which it expects will persist through mid-March, to "the combination of incredible demand coupled with overall global supply constraints."